Metilfenidato Ratiopharm

Methylphenidate hydrochloride, the active ingredient in Metilfenidato Ratiopharm, is a central nervous system stimulant presented as an oral tablet for oral use. It treats attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults. The product conforms to EU pharmaceutical standards and is marketed throughout the European Union.

GNH USA supplies Metilfenidato Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metilfenidato Ratiopharm, a central nervous system stimulant, is indicated for the following conditions:

- Attention deficit hyperactivity disorder (ADHD): improves concentration, reduces hyperactivity and impulsivity in patients of various ages. - Narcolepsy: decreases excessive daytime sleepiness and reduces the frequency of sudden sleep attacks.

Methylphenidate may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced desire for food, potentially affecting weight. - Headache: mild to moderate head pain. - Stomach pain: gastrointestinal discomfort.

Serious or Rare Side Effects: - Arrhythmia: irregular heart rhythm that may require medical attention. - Hypertension: elevated blood pressure. - Psychosis: emergence of hallucinations or delusional thinking.

When prescribing Metilfenidato Ratiopharm, clinicians should observe the following precautions: - Assess cardiovascular status: evaluate blood pressure and heart rate before initiating therapy. - Monitor growth in children: track height and weight regularly. - Avoid use in patients with known hypersensitivity to methylphenidate. - Use caution with concomitant psychiatric disorders: watch for emergence of psychosis or mania. - Avoid abrupt discontinuation: taper under medical supervision. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Methylphenidate can interact with other medicines; the most important are listed below.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: may increase cardiovascular effects. - Antihypertensive agents: may reduce efficacy of blood pressure control.

Moderate Interactions (Monitor Closely): - Alcohol: may increase central nervous system stimulation. - CYP2D6 inhibitors (e.g., fluoxetine): may raise methylphenidate plasma levels.